Clinical trials: Fat; Liver
Non Alcoholic Fatty Liver Disease
Efficacy and Safety of Pemafibrate for Nonalcoholic Fatty Liver Disease
This is a study to evaluate the effect of pemafibrate on fatty liver in patients with hypertgemia combined with NAFLD, using fenofibrate as a control.
- Trial name
- NCT06623539
- Testing
- Pemafibrate high dose, Pemafibrate low dose, Fenofibrate
- Where
- Japan
- Volunteers
- 360 people
- Sponsor
- Yokohama City University
Visceral Fat, Fatty Liver
Visceral Abdominal Fat, Non Alcoholic Fatty Liver Diseases and Asymptomatic Coronary Atherosclerosis
Visceral fat or peri-omental fat is increasingly associated with metabolic syndrome, a condition carrying a high risk of coronary artery disease. The independent role of Visceral Fat in cardiovascular risk remains unclear.
- Conditions
- Visceral Fat, Fatty Liver, Atherosclerosis, Coronary Computed Tomography Angiography
- Trial name
- NCT01282892
- Testing
- excess of visceral fat, patients with NAFLD
- Where
- 2 sites in Israel
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Ziv Hospital
Colorectal Neoplasms, Nonalcoholic Fatty Liver Disease
Study of the Association of Nonalcoholic Fatty Liver Disease With Colorectal Malignant Neoplasm
The aim of this sudy is to investigate the prevalence of colorectal cancer (CRC) in patients with nonalcoholic fatty liver disease (NAFLD) and evaluate whether NAFLD is a risk factor for CRC.
- Trial name
- NWC (NCT01657773)
- Testing
- Ultrasound examination and Colonoscopy examination
- Where
- China
- Volunteers
- 2,315 people, healthy volunteers welcome
- Sponsor
- Wenzhou Medical University
Non Alcoholic Steatohepatitis (NASH)
Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment
The primary objectives of this study are to evaluate the effect of Obeticholic Acid treatment compared to placebo on 1) histological improvement and 2) liver-related clinical outcomes in patients with non-cirrhotic nonalcoholic…
- Trial name
- REGENERATE (NCT02548351)
- Testing
- Obeticholic Acid
- Where
- 346 sites in United States, Australia and 19 more
- Volunteers
- 2,477 people
- Sponsor
- Intercept Pharmaceuticals
Diabete Mellitus, T2 Diabetes and Fatty Liver Disease (Non-alcoholic Origin)
Duodenal pulsENDO as an Early Treatment for Type 2 DM
This study is designed to evaluate the efficacy and safety of endoscopic duodenal re-cellularization therapy using pulsed electric field in individuals with in patients with a recent diagnosis of type 2 diabetes mellitus (T2DM).
- Trial name
- DREAM-1 (NCT07376486)
- Testing
- pulsENDO treatment
- Where
- Hong Kong
- Volunteers
- 40 people
- Sponsor
- Chinese University of Hong Kong
Hepatic Steatosis
Quantitative US for Hepatic Steatosis
The purpose of this study is to investigate the diagnostic performance of quantitative ultrasound imaging parameter for the assessment of hepatic steatosis in patients with non-alcoholic fatty liver disease using magnetic…
- Trial name
- NCT04180631
- Testing
- Quantitative ultrasound imaging parameter (QUS)
- Where
- South Korea
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Obesity, Nonalcoholic Steatohepatitis
ALT-801 (Pemvidutide) in Healthy Overweight and Obese Volunteers to Study Safety and Tolerability
This study was a FIH, Phase 1, randomized, double-blind, placebo-controlled, 2-part single-ascending dose (SAD) and multiple-ascending dose (MAD) study of ALT-801 (pemvidutide) in healthy overweight and obese subjects.
- Trial name
- NCT04561245
- Testing
- ALT-801
- Where
- Australia
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Altimmune, Inc.
NASH - Nonalcoholic Steatohepatitis
Evaluation of Efficacy, Safety and Tolerability of Aldafermin in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study In Subjects With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis (ALPINE 2/3)
This is a multi-center evaluation of NGM282 in a randomized, double-blind, placebo-controlled study administered for 24 weeks in participants with histologically confirmed NASH and F2/F3 Fibrosis.
- Trial name
- NCT03912532
- Testing
- NGM282
- Where
- 37 sites in United States, Puerto Rico
- Volunteers
- 171 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Type2 Diabetes, NAFLD
Effects of VLCD and Bariatric Surgery in Patients With Type 2 Diabetes
The investigators are therefore interested to explore the effects of VLCD and different bariatric surgery procedures to changes in the physical deposition of fat in organs which regulate glucose metabolism (i.e.
- Conditions
- Type2 Diabetes, NAFLD, Obesity
- Trial name
- BARIATRICMRI (NCT05092399)
- Testing
- Bariatric Surgery
- Where
- United Kingdom
- Volunteers
- 21 people
- Sponsor
- University of Nottingham
Non Alcoholic Fatty Liver Disease
UDFF Performance Evaluation ((Ultrason Derived Fat Fraction)
The purpose of this study is to assess UDFF performance (compared to MRI)
- Trial name
- UDFF (NCT06080386)
- Testing
- UDFF
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Angers
Metabolic-associated Fatty Liver Disease, Type 2 Diabetes
Effect of Empagliflozin and Dulaglutide on MAFLD in Patients With T2D
The co-administration of SGLT2 inhibitor and GLP-1 receptor agonist would be safe and effective on glycemic control in subjects with type 2 diabetes mellitus and MAFLD better than empagliflozin or dulaglutide alone.
- Trial name
- NCT05140694
- Testing
- Empagliflozin, Dulaglutide, Empagliflozin and Dulaglutide
- Volunteers
- 135 people
- Sponsor
- Seoul National University Bundang Hospital
Overweight or Obesity, Metabolic Syndrome
Fermented Dairy Products and The Metabolic Syndrome
The study will be conducted as a randomized controlled trial with four parallel arms including four dairy products. We will investigate the health effects of including yogurt in the diet through a 16-weeks intervention period…
- Trial name
- FerMetS (NCT04755530)
- Testing
- Regular whole milk, Yogurt with live bacteria, Yogurt with inactivated bacteria
- Where
- Denmark
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Faidon Magkos
Non-Alcoholic Fatty Liver Disease, Type2diabetes
Efficacy of Empagliflozin and Pioglitazone in Diabetic Patients With NAFLD
This clinical trial will yield results about the therapeutic effect of combining pioglitazone with SGLT2i in people suffering from NAFLD associated with T2DM.
- Trial name
- NCT05942963
- Testing
- Empagliflozin 10 MG, Pioglitazone 15mg, Metformin
- Where
- Pakistan
- Volunteers
- 240 people
- Sponsor
- Jinnah Postgraduate Medical Centre
Obese
Study of NGM313 in Obese Participants
The purpose of the study is to evaulate the safety, tolerability, and efficacy of NGM313 in obese participants
- Trial name
- NCT03298464
- Testing
- NGM313, Pioglitazone
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Nonalcoholic Fatty Liver Disease
A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-963272 in Participants With Nonalcoholic Fatty Liver Disease
The purpose of this study is to evaluate the safety, tolerability, and drug levels of BMS-963272 compared to placebo in participants with nonalcoholic fatty liver disease (NAFLD) and high probability of advanced fibrosis.
- Trial name
- NCT04766476
- Testing
- BMS-963272
- Where
- 19 sites in United States
- Volunteers
- 9 people
- Sponsor
- Bristol-Myers Squibb
Non Alcoholic Fatty Liver Disease
The Effect Of Dual Treatment With L-Carnitine And Magnesium On Fatty Liver
The purpose of this study is to determine whether the dual therapy of the amino acid L-CARNITINE and magnesium have an effect on reducing the liver fat content in patients with non alcoholic fatty liver disease (NAFLD).
- Trial name
- NCT01956825
- Testing
- "slim water"
- Where
- Israel
- Volunteers
- 60 people
- Sponsor
- Meir Medical Center
NAFLD, Diabetes
GLP-1 RA on Liver OMICS in MASLD
In patients with type II diabetes mellitus (T2DM) and obesity, an excess plasma-free fatty acid is found with an associated increased lipid accumulation in adipocytes and liver tissue.
- Conditions
- NAFLD, Diabetes, Obesity
- Trial name
- OMICS in MASLD (NCT06982378)
- Testing
- GLP-1 receptor agonist
- Where
- United States
- Sponsor
- Medical College of Wisconsin
Non-Alcoholic Steatohepatitis (NASH)
Phase IIb Study to Evaluate the Efficacy and Safety of GFT505 Versus Placebo in Patients With Non-Alcoholic Steatohepatitis (NASH)
Abdominal obesity and type-2 Diabetes are associated with chronic liver disorders resulting from the accumulation of fat in the liver (steatosis), which may progress towards hepatitis and possibly lead to cirrhosis and liver…
- Trial name
- NCT01694849
- Testing
- GFT505 80mg, GFT505 120mg
- Where
- 56 sites in United States, Belgium and 7 more
- Volunteers
- 275 people
- Sponsor
- Genfit
Hepatic Transplantation, Steatohepatitis
Diagnosis and Quantification of Hepatic Steatosis Using Near-infrared Spectroscopy
In liver transplantation, the main problem is the shortage of grafts due to the small pool of donors. In order to increase the number of donors, grafts are increasingly being taken from older donors, known as 'expanded criteria'…
- Trial name
- STEATO-NIR (NCT07254533)
- Testing
- Near-infrared spectrometer
- Where
- France
- Volunteers
- 90 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Fatty Liver, Nonalcoholic, Meal Time
Hepatic Glycogen and Fat Oxidation
Excessive fat in the liver is associated with impairments in metabolic health. Low levels of DNL and high levels of hepatic fat oxidation are considered to be protective.
- Conditions
- Fatty Liver, Nonalcoholic, Meal Time, Fasting, Glycogen Depletion
- Trial name
- NCT03593343
- Testing
- Overnight fasting duration
- Where
- Netherlands
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Maastricht University Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.